a virtual twin model to simulate patient-specific response, toxicity, and resistance to CAR T-cell therapy in relapsed/refractory myeloma.

Virtual twins for personalised CAR T-cell therapy in myeloma - The Lancet Haematology

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma. @FDAOncology.

RT @SocietyofHemOnc: ICYMI: FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma . .

I’m impressed by the 100% ORR in dual-antigen–naïve RRMM pts—JNJ-5322 could rival CAR-Ts without the wait. That said, durability is still a question, and 28% gr 3/4 infection rate isn’t trivial. Promising, but needs longer follow-up. #ASH2025 #MM.

Phase 1 (NCT05652335) enrolled RRMM 126 pts (36 at RP2D 100 mg Q4W; median 4 prior lines; all triple-class exposed: At RP2D:.• ORR = 100% in dual-antigen–naïve pts (n=27).• ORR = 86% overall (n=36).• CRS = 59% (all gr 1–2), ICANS rare (2%, all gr 1).• Infections gr 3/4 = 28%.

#asco2025 Update: JNJ-5322 is a next-gen T-cell redirecting bispecific antibody targeting BCMA + GPRC5D with low-affinity CD3 for improved safety. SubQ dosing Q2W or Q4W. Step-up dose (5 mg) used to reduce CRS risk. #MultipleMyeloma #Immunotherapy

RT @MostafaFaisal14: How I approach hematopoietic stem cell transplantation for CML in a TKI world @BloodJournal.

RT @Nature: These are the 25 most cited papers published in the twenty-first century.

RT @DrHKantarjian: Check out our comprehensive review on #AML from an @MDAndersonNews perspective, " Therapeutic horizon of acute myeloid l….

RT @Myeloma_Doc: #Myeloma Paper of the Day: CASSIOPEIA #MRD data show dara maintenance improved MRD-negative rates vs. observation regardle….

The BALANCE trial demonstrated that a 7-day antibiotic treatment strategy is non-inferior to a 14-day strategy for hospitalized patients with bloodstream infections. Limitation in context of HCT: Pts with severe immunosuppression were excluded

RT @TalhaBadarMD: Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML https://t.co….

RT @LeukDocJZ: Hot Off the Press 🚨🚨🚨ENHANCE-2- Randomized P3 Study of Aza/Magrolimab vs Physician Choice in Newly Dx TP53-mut AML- publishe….

NRM at 2 years: 4.8%.EFS at 2 years: 88%.OS at 2 years: 95%.G3-4 aGVHD at day 100: 4.8% .cGVHD at 2 years: 22.4%.Graft failure rate: 7.1%.Off immunosuppression therapy at 1 year: 97%.

Graft: non-GCSF-mobilized BM grafts from first-degree haploidentical relatives.

Intervention:.Hydroxyurea: 30 mg/kg/day for 60 days as preconditioning (day -70 to day -10). Conditioning : Thymoglobulin 4.5 mg/kg, Thiotepa 10 mg/kg, Cy 29 mg/kg total, Flu 150 mg/m² total, TBI 200-cGy .GVHD prophylaxis: Cy 50 mg/kg on days +3 and +4.

Phase 2, open-label, single-arm, multicenter study (BMT CTN 1507). Participants: Adults with severe sickle cell disease. 54 enrolled. 42 transplanted.

🚨 New study in NEJM Evidence: Haploidentical BMT with posttransplant cyclophosphamide in adults with sickle cell disease!.@BMTCTN @SCDAAorg @SCDFoundation @DrAdetolaKassim .

RT @MM_Hub: ⭐ Multiple Myeloma spotlight: Latest survival and efficacy data from the phase III DREAMM-7 trial ⭐. During #ASH24, @dra_v_hung….